Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 6,139 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Motor Activity Clear all
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B

NCT01590641
View directory record Official record
Conditions
Hepatitis B, HBV
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder

NCT03533556
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-theanine, Caffeine, L-theanine-Caffeine Combination, Placebo
Dietary Supplement · Other
Lead sponsor
Texas Tech University
Other
Eligibility
8 Years to 17 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 21, 2026, 2:34 AM EDT
Completed No phase listed Observational

Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy

NCT00209066
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

NCT07706556
View directory record Official record
Conditions
Breast Cancer
Interventions
Affect-based Exercise Prescription, Effort-based exercise prescription, Standard Exercise Promotion Program, Step-up Exercise Promotion Program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

NCT05607420
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Interventions
UCART20x22, CLLS52
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using a Telehealth and Shared Decision-Making Model to Address Preventative Medicine Strategies Among Communities in Louisiana

NCT05676970
View directory record Official record
Conditions
Preventative Medicine
Interventions
Telehealth: Personalized Preventative Medicine Strategies, TeleHealth: Preventative Medicine Education
Behavioral
Lead sponsor
Xavier University of Louisiana.
Other
Eligibility
18 Years to 55 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Suspended Phase 1 Interventional

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

NCT04650451
View directory record Official record
Conditions
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
Interventions
chimeric antigen receptor (CAR) T cell therapy
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Duarte, California • La Jolla, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

NCT06287229
View directory record Official record
Conditions
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Interventions
Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

NCT03787680
View directory record Official record
Conditions
Prostate Cancer
Interventions
Olaparib, AZD6738
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Active, not recruiting Not applicable Interventional

Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)

NCT05375162
View directory record Official record
Conditions
Cancer
Interventions
Core Intervention, E-Coach, General Mindfulness Training, MVPA-Specific Mindfulness Training, Buddy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 39 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial

NCT07387705
View directory record Official record
Conditions
Sleep, Physical Activity, First Episode Psychosis
Interventions
On Track for Wellness
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Not listed
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

NCT01980056
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Vosaroxin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients

NCT02757131
View directory record Official record
Conditions
Weakness, Hospital Acquired Condition
Interventions
Ambulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

NCT04587479
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
JAB-8263
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Denver, Colorado • Lake City, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Koa Family: California's Obesity Prevention Project

NCT03605888
View directory record Official record
Conditions
Weight Loss, Diet Habit, Physical Activity, Overweight and Obesity
Interventions
Koa Family
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 47 Years · Female only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Effects of a Partially Supervised Conditioning Program in CF

NCT01744561
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Exercise Intervention
Behavioral
Lead sponsor
Wuerzburg University Hospital
Other
Eligibility
12 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional Results available

Children's Use of the Built Environment for Physical Activity

NCT01939405
View directory record Official record
Conditions
Obesity, Overweight
Interventions
built environment use counseling
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
10 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Revere, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 21, 2026, 2:34 AM EDT
Not listed Not applicable Interventional

FE-SaLiR: Function Improvement Exercise

NCT04284137
View directory record Official record
Conditions
Disability Physical, Cognitive Impairment
Interventions
Modified FE-SaLiR, Unmodified Chinese Medicine Exercise, Active Control
Behavioral
Lead sponsor
The University of Texas at San Antonio
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

NCT07567846
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions
GDC-1261
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Bemobile Intervention to Support Physical Activity in Cancer Survivors

NCT02824861
View directory record Official record
Conditions
Cancer
Interventions
Bemobile
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
22 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 21, 2026, 2:34 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

NCT06440005
View directory record Official record
Conditions
Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor, Breast Cancer, Prostate Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Angiosarcoma, Solid Tumor
Interventions
AGX101
Drug
Lead sponsor
Angiex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Sarasota, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hemp Fiber Ingestion and Gut Permeability After Exercise

NCT06204666
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Metabolic Disturbance
Interventions
High Dose Hemp Fiber Bar, Low Dose Hemp Fiber Bar, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 2:34 AM EDT
Completed Phase 4 Interventional

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

NCT05139472
View directory record Official record
Conditions
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
Interventions
Empagliflozin 10 MG
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 2:34 AM EDT